At GCOS 2025, the International Cardio-Oncology Society (IC-OS) announced a major leadership transition, marking the conclusion of Dr. Susan Dent’s presidency and the beginning of Dr. Michael Fradley’s term as President.
Dr. Susan Dent will complete her term as President of IC-OS in 2025, concluding years of visionary leadership that have significantly shaped the growth and direction of the society worldwide.
“Today, we formally announced that Dr. Susan Dent’s term as IC-OS President will come to an end in 2025. Dr. Dent has been a fearless leader over her three-year term – advancing cardio-oncology around the world and helping our society grow. We thank her for all her contributions.” – shared International Cardio-Oncology Society.
During her tenure, Dr. Susan Dent has played a truly pivotal role in shaping the global landscape of cardio-oncology. Under her leadership, IC-OS has expanded its international presence, forged new partnerships across continents, and strengthened collaborations among clinicians, researchers, and patient advocates. She has championed groundbreaking educational programs and research initiatives that have significantly advanced the understanding and management of cardiovascular health in cancer patients and survivors.
Dr. Michael Fradley, will assume the role of President of IC-OS beginning January 1, 2026. A respected leader in the field and long-time board member, Dr. Fradley has contributed extensively to the society’s mission through his research, education, and clinical leadership. His appointment marks a new era for IC-OS, ensuring continuity of excellence and further growth in advancing cardiovascular care for oncology patients worldwide.
“We’re pleased to announce Dr. Michael Fradley as our incoming President,” IC-OS said. “Michael has been a long-time board member, and we look forward to his continued leadership as he steps into this new role.”
About Dr. Michael Fradley
Dr. Fradley is an attending cardiologist/electrophysiologist, Medical Director of the Penn Cardio-Oncology Program, and Associate Professor of Clinical Medicine at the University of Pennsylvania.
He completed his undergraduate degree at Yale University in Molecular Biophysics and Biochemistry (cum laude, with distinction in major) and earned his MD at the Johns Hopkins School of Medicine, where he also completed his residency in Internal Medicine through the Osler Medical Residency Program.
He went on to complete fellowships in Cardiology and Clinical Cardiac Electrophysiology at Massachusetts General Hospital. Dr. Fradley’s research focuses on the treatment and prevention of cardiovascular disease in cancer patients and survivors. He has published extensively and served on numerous committees, including the Massachusetts Medical Society Committee on Medical Education and the University of South Florida LCME Faculty Affairs Committee.
You Can Also Read: ASCO24 Updates: Cardiac Health and Cancer Treatment with Michael Fradley
Written by Lena Mkrtchyan, MD
